General Information of Drug (ID: DM96YR2)

Drug Name
CCNCSSKWCRAHSRCC
Synonyms CHEMBL524475
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1840.2
Topological Polar Surface Area (xlogp) -9.4
Rotatable Bond Count (rotbonds) 24
Hydrogen Bond Donor Count (hbonddonor) 30
Hydrogen Bond Acceptor Count (hbondacc) 31
Chemical Identifiers
Formula
C69H106N28O20S6
IUPAC Name
(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-18-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontane-56-carboxamide
Canonical SMILES
C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC4=CNC5=CC=CC=C54)CCCCN)CO)CO)CC(=O)N)CCCNC(=N)N)CO)CC6=CN=CN6
InChI
InChI=1S/C69H106N28O20S6/c1-31-53(103)87-41(17-33-20-78-30-82-33)59(109)90-43(21-98)61(111)85-39(12-7-15-80-69(76)77)57(107)95-50-29-123-122-26-47-65(115)89-42(18-51(72)101)60(110)97-49(28-121-119-25-46(52(73)102)93-67(50)117)66(116)92-45(23-100)63(113)91-44(22-99)62(112)84-37(10-4-5-13-70)56(106)88-40(16-32-19-81-36-9-3-2-8-34(32)36)58(108)96-48(27-120-118-24-35(71)54(104)94-47)64(114)86-38(55(105)83-31)11-6-14-79-68(74)75/h2-3,8-9,19-20,30-31,35,37-50,81,98-100H,4-7,10-18,21-29,70-71H2,1H3,(H2,72,101)(H2,73,102)(H,78,82)(H,83,105)(H,84,112)(H,85,111)(H,86,114)(H,87,103)(H,88,106)(H,89,115)(H,90,109)(H,91,113)(H,92,116)(H,93,117)(H,94,104)(H,95,107)(H,96,108)(H,97,110)(H4,74,75,79)(H4,76,77,80)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
InChIKey
RFBOHZPDDZVGLQ-CPQFHPGLSA-N
Cross-matching ID
PubChem CID
44560061
TTD ID
D01YPT

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.4 (SCN4A) TT84DRB SCN4A_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
2 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
3 Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
4 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
5 Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.